The stock of Acadia Pharmaceuticals Inc (ACAD) has seen a -7.25% decrease in the past week, with a -11.18% drop in the past month, and a -2.95% decrease in the past quarter. The volatility ratio for the week is 3.44%, and the volatility levels for the past 30 days are at 4.13% for ACAD.. The simple moving average for the past 20 days is -10.75% for ACAD’s stock, with a 0.13% simple moving average for the past 200 days.
Is It Worth Investing in Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Right Now?
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) has a price-to-earnings ratio that is above its average at 12.33x. The stock has a 36-month beta value of 0.52. Opinions on the stock are mixed, with 6 analysts rating it as a “buy,” 6 as “overweight,” 7 as “hold,” and 0 as “sell.”
The public float for ACAD is 165.50M, and at present, short sellers hold a 8.70% of that float. On March 13, 2025, the average trading volume of ACAD was 2.55M shares.
ACAD) stock’s latest price update
The stock of Acadia Pharmaceuticals Inc (NASDAQ: ACAD) has decreased by -2.44 when compared to last closing price of 17.19.Despite this, the company has seen a loss of -7.25% in its stock price over the last five trading days. businesswire.com reported 2025-03-05 that SAN DIEGO–(BUSINESS WIRE)–Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the journal Med published results from the open-label study, DAFFODIL™, evaluating the safety, tolerability and exploratory efficacy of DAYBUE® (trofinetide) in girls ages two to four living with Rett syndrome (n = 15). The long-term Phase 2/3 study demonstrated DAYBUE had a similar safety profile in children two to four years of age as that observed in individuals with Rett syndrome five years of age an.
Analysts’ Opinion of ACAD
Many brokerage firms have already submitted their reports for ACAD stocks, with Deutsche Bank repeating the rating for ACAD by listing it as a “Hold.” The predicted price for ACAD in the upcoming period, according to Deutsche Bank is $22 based on the research report published on February 11, 2025 of the current year 2025.
Guggenheim, on the other hand, stated in their research note that they expect to see ACAD reach a price target of $20, previously predicting the price at $23. The rating they have provided for ACAD stocks is “Neutral” according to the report published on January 03rd, 2025.
ACAD Trading at -8.83% from the 50-Day Moving Average
After a stumble in the market that brought ACAD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -18.91% of loss for the given period.
Volatility was left at 4.13%, however, over the last 30 days, the volatility rate increased by 3.44%, as shares sank -9.30% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.45% lower at present.
During the last 5 trading sessions, ACAD fell by -7.25%, which changed the moving average for the period of 200-days by +6.01% in comparison to the 20-day moving average, which settled at $18.79. In addition, Acadia Pharmaceuticals Inc saw -8.61% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ACAD starting from GAROFALO ELIZABETH A., who sale 4,919 shares at the price of $18.23 back on Mar 05 ’25. After this action, GAROFALO ELIZABETH A. now owns 17,595 shares of Acadia Pharmaceuticals Inc, valued at $89,673 using the latest closing price.
GAROFALO ELIZABETH A., the Director of Acadia Pharmaceuticals Inc, proposed sale 4,919 shares at $18.23 during a trade that took place back on Mar 05 ’25, which means that GAROFALO ELIZABETH A. is holding shares at $89,673 based on the most recent closing price.
Stock Fundamentals for ACAD
Current profitability levels for the company are sitting at:
- 0.24 for the present operating margin
- 0.91 for the gross margin
The net margin for Acadia Pharmaceuticals Inc stands at 0.24. The total capital return value is set at 0.29. Equity return is now at value 38.89, with 23.39 for asset returns.
Based on Acadia Pharmaceuticals Inc (ACAD), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at 3.03.
Currently, EBITDA for the company is 100.16 million with net debt to EBITDA at -2.74. When we switch over and look at the enterprise to sales, we see a ratio of 2.64. The receivables turnover for the company is 9.15for trailing twelve months and the total asset turnover is 0.81. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.38.
Conclusion
To sum up, Acadia Pharmaceuticals Inc (ACAD) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
